Joe Pazona and co-host Cat Williams discuss GLP-1 agonists, often referred to as miracle weight loss drugs, in a new episode of the Balls Deep podcast
Livadas S, Androulakis I, Angelopoulos N, Lytras A, Papagiannopoulos F, Kassi G
This dominance reflects the current treatment paradigm where GLP-1 medications are primarily positioned and reimbursed for obesity management based on BMI criteria rather than cardiovascular risk reduction
HDV increases the risk of cirrhosis threefold [10] and the incidence of HCC up to 9 fold compared to HBV monoinfection [11, 12]
The FDA did not approve BPC-157, KPV, TB-500, MOTS-c, Epitalon, or Semax through this advisory process
Final Word BPC-157 may well prove to be one of the most important tools in sports medicine and regenerative care